<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889667</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-009</org_study_id>
    <secondary_id>ORMD-0801</secondary_id>
    <nct_id>NCT01889667</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With T2DM Who Are Inadequately Controlled With Diet and Exercise or Diet, Exercise and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and pharmacodynamics of an oral formulation&#xD;
      of insulin in subjects with Type 2 Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, Phase II(a), randomized, double-blind, placebo-controlled, parallel&#xD;
      group, inpatient study preceded by a 5-day single-blind outpatient placebo run-in period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Safety and Tolerability of ORMD-0801.</measure>
    <time_frame>Eight (8) days</time_frame>
    <description>Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)</measure>
    <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
    <description>Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)</measure>
    <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
    <description>Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Morning Fasting Serum Insulin</measure>
    <time_frame>Screening, Day 2. Day 9</time_frame>
    <description>Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo</measure>
    <time_frame>Screening, Day 2, Day 9</time_frame>
    <description>Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose # 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Insulin Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose # 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Insulin Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oil Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 Dose # 1</intervention_name>
    <description>Oral Insulin Formulation</description>
    <arm_group_label>ORMD-0801 Dose # 1</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 Dose # 2</intervention_name>
    <description>Oral Insulin Formulation</description>
    <arm_group_label>ORMD-0801 Dose # 2</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oil Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, age 20 to 70 years, inclusive with T2DM;&#xD;
&#xD;
          -  At randomization, patients are treated for diabetes by diet and exercise, or by diet,&#xD;
             exercise and metformin (&gt;1000 mg/day; any type and regimen). Patients on a stable&#xD;
             regimen of metformin (defined as the same metformin dose and type) for at least 6&#xD;
             weeks prior to entering the placebo run-in period. Other anti-diabetic agents not in&#xD;
             use for the 6 weeks prior to entering the placebo run-in period;&#xD;
&#xD;
          -  25 kg/m2 ≤ BMI ≤ 40 kg/m2&#xD;
&#xD;
          -  6.5% ≤ HbA1c ≤ 10.5%, prior to randomization)&#xD;
&#xD;
          -  Fasting plasma glucose ≥ 126 mg/dL (8.3 mmo1/L) prior to randomization;&#xD;
&#xD;
          -  No tobacco or nicotine use within 10 wks prior to screening;&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative serum pregnancy test result at&#xD;
             screening and a negative urine pregnancy test at Visit 3. Females of non-childbearing&#xD;
             potential are defined as postmenopausal who:&#xD;
&#xD;
               1. had more than 24 months since last menstrual cycle with menopausal levels of FSH;&#xD;
&#xD;
               2. age &gt; 55 years old; or&#xD;
&#xD;
               3. are surgically menopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any clinically significant endocrine disease according to the PI;&#xD;
&#xD;
          -  Clinical diagnosis of T1DM;&#xD;
&#xD;
          -  Fasting plasma glucose &gt; 260 mg/dL at the end of washout/stabilization/run-in periods;&#xD;
&#xD;
          -  Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤ 50 mg/dL in the&#xD;
             absence of symptoms of hypoglycemia;&#xD;
&#xD;
          -  Presence of any clinically significant condition that might interfere with the&#xD;
             evaluation of study medication;&#xD;
&#xD;
          -  Presence or history of cancer within the past 5 yrs. with the exception of&#xD;
             adequately-treated localized basal cell skin cancer or in situ uterine cervical&#xD;
             cancer;&#xD;
&#xD;
          -  Laboratory abnormalities at screening:&#xD;
&#xD;
               1. C-peptide &lt; 1.0 ng/mL;&#xD;
&#xD;
               2. Positive pregnancy test in females of childbearing potential (at screening and&#xD;
                  start of run-in period);&#xD;
&#xD;
               3. Abnormal TSH levels &gt; 1.5 x the upper limit of normal;&#xD;
&#xD;
               4. Positive test for hepatitis B surface antigen and/or hepatitis C antibody;&#xD;
&#xD;
               5. Positive test for HIV;&#xD;
&#xD;
               6. Any relevant abnormality interfering with the efficacy or the safety assessments&#xD;
                  during study drug administration;&#xD;
&#xD;
          -  Use of the following medications&#xD;
&#xD;
               1. History of use of insulin for no more than 1 wk in the last 6 mos and none in the&#xD;
                  last 6 wks prior to randomization;&#xD;
&#xD;
               2. History of use of aprotinin at any time prior to the screening visit;&#xD;
&#xD;
               3. Administration of anti-diabetic drugs other than metformin within 6 wks prior to&#xD;
                  run-in period;&#xD;
&#xD;
               4. Administration of thiazolidinedione treatment within 3 months prior to&#xD;
                  randomization;&#xD;
&#xD;
               5. Administration of thyroid preparations or thyroxine (except in patients on stable&#xD;
                  replacement therapy) within 6 weeks prior to screening visit;&#xD;
&#xD;
               6. Administration of systemic long-acting corticosteroids within two months or&#xD;
                  prolonged use of other systemic corticosteroids or inhaled corticosteroids within&#xD;
                  30 days prior to screening visit;&#xD;
&#xD;
               7. Use of medications known to modify glucose metabolism or to decrease the ability&#xD;
                  to recover from hypoglycemia such as oral, parenteral, and inhaled steroids, beta&#xD;
                  blockers (with the exception of beta blocker ophthalmic solutions for glaucoma or&#xD;
                  ocular hypertension), and immunosuppressive or immunomodulating agents.&#xD;
&#xD;
          -  History of severe or multiple allergies;&#xD;
&#xD;
          -  History of tobacco or nicotine use within 10 wks prior to screening&#xD;
&#xD;
          -  Patient is on a weight loss program and is not in the maintenance phase, or patient&#xD;
             that started weight loss medication within 8 wks prior to screening;&#xD;
&#xD;
          -  Pregnancy or breast-feeding;&#xD;
&#xD;
          -  Patient has a screening visit systolic blood pressure of ≥165 mm Hg or diastolic blood&#xD;
             pressure of ≥100 mm Hg. Patients will be allowed to take a BP rescue medication as&#xD;
             long as it does not affect glucose metabolism (e.g., diuretics) or sensation of&#xD;
             hypoglycemia (e.g., beta-blockers);&#xD;
&#xD;
          -  Patient is, at the time of signing informed consent, a user of recreational or illicit&#xD;
             drugs or has had a recent history (within the last year) of drug or alcohol abuse or&#xD;
             dependence;&#xD;
&#xD;
          -  Elevated liver enzymes ALT, AST, alkaline phosphatase) &gt; 2 x the upper limit of normal&#xD;
             at screening;&#xD;
&#xD;
          -  Very high triglyceride level (&gt;600 mg/dL) at screening;&#xD;
&#xD;
          -  ECG abnormality at screening or CV. Clinically significant CV will include&#xD;
&#xD;
               1. history of stroke, transient ischemic attack, or MCI within 6 months prior to&#xD;
                  screening;&#xD;
&#xD;
               2. history of or currently have NYHA Class II-IV heart failure prior to screening;&#xD;
                  or&#xD;
&#xD;
               3. uncontrolled hypertension defined as BP ≥180 mmHg (systolic) or ≥110 mmHG&#xD;
                  (diastolic) at screening or at Visit 2;&#xD;
&#xD;
          -  One or more contraindications to metformin;&#xD;
&#xD;
          -  History of gastrointestinal disorders with the potential to interfere with drug&#xD;
             absorption;&#xD;
&#xD;
        At the Principal Investigator's discretion, any condition or other factor that is deemed&#xD;
        unsuitable for patient enrollment into the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel M Neutel, M. D.</last_name>
    <role>Study Director</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <results_first_submitted>April 28, 2014</results_first_submitted>
  <results_first_submitted_qc>October 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2014</results_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Insulin</keyword>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ORMD-0801 Dose # 1</title>
          <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation</description>
        </group>
        <group group_id="P2">
          <title>ORMD-0801 Dose # 2</title>
          <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ORMD-0801 Dose # 1</title>
          <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
        </group>
        <group group_id="B2">
          <title>ORMD-0801 Dose # 2</title>
          <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="4.9"/>
                    <measurement group_id="B2" value="57.4" spread="4.7"/>
                    <measurement group_id="B3" value="53.6" spread="12.0"/>
                    <measurement group_id="B4" value="55.3" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Safety and Tolerability of ORMD-0801.</title>
        <description>Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug</description>
        <time_frame>Eight (8) days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Safety and Tolerability of ORMD-0801.</title>
          <description>Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug</description>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
        <description>Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801</description>
        <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
        <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
          <description>Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801</description>
          <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
          <units>mg/DL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Last two days (day 6 and day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.64" spread="39.400"/>
                    <measurement group_id="O2" value="150.24" spread="49.264"/>
                    <measurement group_id="O3" value="167.95" spread="64.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Seven Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.73" spread="38.861"/>
                    <measurement group_id="O2" value="149.38" spread="38.249"/>
                    <measurement group_id="O3" value="165.85" spread="60.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
        <description>Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801</description>
        <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
        <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
          <description>Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801</description>
          <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Seven Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.55" spread="36.986"/>
                    <measurement group_id="O2" value="163.05" spread="30.282"/>
                    <measurement group_id="O3" value="175.99" spread="61.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last two days (day 6 and day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.23" spread="40.160"/>
                    <measurement group_id="O2" value="158.58" spread="40.672"/>
                    <measurement group_id="O3" value="176.06" spread="63.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Morning Fasting Serum Insulin</title>
        <description>Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
        <time_frame>Screening, Day 2. Day 9</time_frame>
        <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Morning Fasting Serum Insulin</title>
          <description>Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
          <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.80" spread="18.984"/>
                    <measurement group_id="O2" value="17.34" spread="12.225"/>
                    <measurement group_id="O3" value="34.51" spread="64.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.93" spread="10.122"/>
                    <measurement group_id="O2" value="12.94" spread="7.472"/>
                    <measurement group_id="O3" value="9.01" spread="4.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.70" spread="8.559"/>
                    <measurement group_id="O2" value="15.51" spread="14.924"/>
                    <measurement group_id="O3" value="9.85" spread="3.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo</title>
        <description>Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
        <time_frame>Screening, Day 2, Day 9</time_frame>
        <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo</title>
          <description>Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
          <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.233" spread="2.3869"/>
                    <measurement group_id="O2" value="3.125" spread="1.3372"/>
                    <measurement group_id="O3" value="5.159" spread="4.9825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.180" spread="1.6593"/>
                    <measurement group_id="O2" value="3.064" spread="0.9200"/>
                    <measurement group_id="O3" value="2.400" spread="0.9419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.875" spread="1.6927"/>
                    <measurement group_id="O2" value="3.090" spread="1.1021"/>
                    <measurement group_id="O3" value="2.715" spread="0.8506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ORMD-0801 Dose # 1</title>
          <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 1: Oral Insulin Formulation (16 mg)</description>
        </group>
        <group group_id="E2">
          <title>ORMD-0801 Dose # 2</title>
          <description>Oral Insulin Formulation&#xD;
ORMD-0801 Dose # 2: Oral Insulin Formulation (24 mg)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Oil Capsules&#xD;
Placebo: Oil Capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>number</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Oramed</organization>
      <phone>+972-2-566-0001</phone>
      <email>aviva@oramed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

